The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia

被引:65
|
作者
Desgrandchamps, F
De la Taille, A
Doublet, JD
机构
[1] Hop St Louis, Dept Urol, F-75475 Paris 10, France
[2] Hop Henri Mondor, Dept Urol, F-94010 Creteil, France
[3] Tenon Hosp, Dept Urol, Paris, France
关键词
acute urinary retention; trial without catheter; alpha; 1-blocker; BPH; alfuzosin;
D O I
10.1111/j.1464-410X.2006.06109.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To evaluate current practice in the management of acute urinary retention (AUR) in men with benign prostatic hyperplasia (BPH) in France. Patients and Methods In all, 2618 men (median age 72 years) presenting with non-febrile AUR were enrolled by 658 French urologists in a prospective cross-sectional survey. The patients' demography, history of BPH, type of AUR and its management (trial without catheter, TWOC, use of alpha(1)-blockers, immediate or elective surgery, other alternatives) were collected. Results Of the 2618 men analysed, 1875 (71.6%) had spontaneous AUR (sAUR) and 743 (28.4%) had precipitated AUR (pAUR), mainly after surgery with locoregional or general anaesthesia. BPH was revealed by AUR in 52.3% of men with pAUR and 25.9% of men with sAUR. A urethral catheter was inserted in most cases (82.7%) while only 16.7% had a suprapubic catheter. After initial catheterization, 72.8% of men had a TWOC (pAUR 89.4%, sAUR 66.2%, P < 0.001) after a median of 3 days of catheterization, 17.9% had elective surgery after a median of 8 days of catheterization (pAUR 7.1%, sAUR 22.1%, P < 0.001), 5.7% had immediate surgery after a median of 4 days of catheterization (pAUR 1.1%, sAUR 7.5%, P < 0.001), 0.4% had a urethral stent inserted and 1.1% had an indwelling catheter. Of the 1906 men who had a TWOC, 79% received an alpha(1)-blocker (mainly alfuzosin) before catheter removal. The TWOC was successful in 50.2% of men (pAUR 52.3%, sAUR, 49.0%, P = 0.17) and the success rate was significantly higher in men receiving an alpha(1)-blocker (53.0% vs 39.6%, P < 0.001) before the TWOC. If the TWOC failed, 33.4% had a second TWOC (pAUR 39.9%, sAUR 30.2%, P = 0.003) after a median of 7 days re-catheterization, 57.5% had elective surgery (pAUR 49.1%, sAUR, 61.7%, P < 0.001) after a median of 8 days re-catheterization, 1.5% had a stent inserted and 1.1% had an indwelling catheter. The overall success rate of a second TWOC was 25.9% (pAUR 32.2%, sAUR 21.9%, P = 0.04). Men catheterized for > 3 days had a slightly lower success rate for TWOC, greater comorbidity and double the rate of prolonged hospitalization due to adverse events than those catheterized for <= 3 days. Conclusions TWOC after a median of 3 days of catheterization has become standard practice in France for men with BPH and AUR. alpha(1)-blockade before a TWOC significantly increases the chance of a successful TWOC. If the TWOC fails, only a quarter of men will have a successful second TWOC. All efforts should be made to reduce the duration of catheterization, to reduce the comorbidity.
引用
收藏
页码:727 / 733
页数:7
相关论文
共 50 条
  • [31] Questionnaire survey of urologists' initial treatment practices for acute urinary retention secondary to benign prostatic hyperplasia in Korea
    Ku, JH
    Kim, SW
    Paick, JS
    UROLOGIA INTERNATIONALIS, 2006, 76 (04) : 314 - 320
  • [32] New methodology to estimate the burden of acute urinary retention (AUR) potentially attributable to benign prostatic hyperplasia (BPH) in France
    Lukacs, B.
    Torreton, E.
    Cotte, F. E.
    Benjamin, L.
    Slama, A.
    Lafuma, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E223 - U644
  • [33] Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, and Urinary Retention
    Alawamlh, Omar Al Hussein
    Goueli, Ramy
    Lee, Richard K.
    MEDICAL CLINICS OF NORTH AMERICA, 2018, 102 (02) : 301 - +
  • [34] Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia
    Slawin, KM
    Kattan, MW
    Roehrborn, CG
    Wilson, T
    UROLOGY, 2006, 67 (01) : 84 - 88
  • [35] Teverelix is a potential treatment option for the prevention of acute urinary retention recurrence in men suffering from benign prostatic hyperplasia
    Ulys, Albertas
    Cerniauskiene, Ausra
    Geavlete, Petrisor
    Larsen, Finn
    Maclean, Carol M.
    van Os, Steve
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2025, 57 (02) : 427 - 433
  • [36] Escitalopram-Associated Acute Urinary Retention in Elderly Men With Known or Latent Benign Prostatic Hyperplasia: A Case Series
    Ferentinos, Panagiotis
    Margaritis, Dimitrios
    Douzenis, Athanasios
    CLINICAL NEUROPHARMACOLOGY, 2016, 39 (06) : 327 - 328
  • [37] Resistive Index as Risk Factor for Acute Urinary Retention in Patients With Benign Prostatic Hyperplasia
    Shinbo, Hitoshi
    Kurita, Yutaka
    Takada, Sanki
    Imanishi, Takeshi
    Otsuka, Atsushi
    Furuse, Hiroshi
    Nakanishi, Toshimasa
    Mugiya, Soichi
    Ozono, Seiichiro
    UROLOGY, 2010, 76 (06) : 1440 - 1445
  • [38] COMBINATED THERAPY IN TH TREATMENT OF ACUTE URINARY RETENTION CAUSED BY BENIGN PROSTATIC HYPERPLASIA
    Ferko, S. H.
    Ndoj, A.
    Janko, A.
    Ibrushi, I.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (06) : 600 - 600
  • [39] Transition zone index as a risk factor for acute urinary retention in benign prostatic hyperplasia
    Kurita, Y
    Masuda, H
    Terada, H
    Suzuki, K
    Fujita, K
    UROLOGY, 1998, 51 (04) : 595 - 600
  • [40] The Effect of Sublingual Isosorbide Dinitrate on Acute Urinary Retention Due to Benign Prostatic Hyperplasia
    Tadayyon, Farhad
    Izadpanahi, MohammadHossein
    Aali, Saeed
    Mazdak, Hamid
    Khorrami, Mohammad-Hatef
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2012, 23 (04) : 782 - 785